The meeting report from Euroscicon’s 2014 Pregnancy Summit, which took place in London (from 6th-8th October), includes several presentations on pre-eclampsia research, treatment and management and technologies used to assess pregnancy-associated conditions.
Meeting Chairs:
Mr Joost Schuitemaker, Managing Director, IQ Products, The Netherlands
Dr Stella Nowicki, Professor Microbiology and Immunology, Meharry Medical College, Nashville, TN, USA
Dr Anne Parle-McDermott, Lecturer in Genetics, Dublin City University, Ireland
Author: Ms Isabella Atieno Ochieng
Nurse/DCH, Reproductive Health Advisor, Jhpiego, South Sudan
Editor: Dr. Astrid Englezou, Euroscicon Ltd
Buy From [amazon asin=B00YQ285FK&text=Amazon]
Contents
INTRODUCTION
Syncytiotrophoblast extracellular vesicles from pre-eclamptic patients affect platelet function.
Porting Novel Pre-eclampsia Diagnostic Tools to the Clinical Market: Co-Development of Two Complementary Technologies.
Pre-eclampsia and the immune system
Pre-eclampsia: four decades of clinical care and the aetiology remains elusive.
Pre-eclampsia – the charity perspective.
Alex Da Costa: my experience of pre-eclampsia.
CONCLUSION.
REFERENCES.
SPEAKERS ABSTRACTS.
POSTER PRESENTATIONS.
PLASMA BIOMARKERS FOR EARLY IDENTIFICATION OF WOMEN AT RISK FOR PRE-ECLAMPSIA.
THE OUTCOME OF PERINATAL MANAGEMENT OF FOETAL GROWTH RESTRICTION IN TERTIARY-CARE UNIT IN POLAND.
CHROMOSOMAL ABNORMALITIES IDENTIFIED AT PRENATAL DIAGNOSIS OF 7050 PREGNANCIES IN TURKEY.
METHYLENTETRAHYDROFOLATE REDUCTASE (MTHFR) C677T POLYMORPHISM AND RISK OF PRE-ECLAMPSIA IN TURKISH PREGNANT WOMEN.
THE PRERATIO STUDY IS THE SFLT-1/PIGF RATIO A SUITABLE MARKER TO DIAGNOSE PRE-ECLAMPSIA AND TO PREDICT ITS ADVERSE MATERNAL/NEONATAL OUTCOMES .
Format: Kindle Edition
File Size: 1165 KB
Print Length: 38 pages
Simultaneous Device Usage: Unlimited
Publisher: HONNAO (1 Jun. 2015)
Sold by: Amazon Media EU S.à r.l.
Language: English
ASIN: B00YQ285FK
